Cassava Sciences to Hold Corporate Update on November 25th
Cassava Sciences (NASDAQ: SAVA) announced it will host a corporate update via conference call and webcast on Monday, November 25th at 8:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cassava Sciences (NASDAQ: SAVA) announced it will host a corporate update via conference call and webcast on Monday, November 25th at 8:00 AM ET. The biotechnology company, which focuses on developing novel Alzheimer's disease treatments, will make the webcast available through their website, with a replay accessible for 90 days following the event on the Company Presentations page.
Details
News Market Reaction – SAVA
The recorded move for SAVA in the trading session of this news was -83.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast planned for Monday, November 25th at 8:00 AM ET
AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.
| Event Details: | |
| Date: | Monday, November 25th |
| Time: | 8:00 a.m. Eastern Time |
| Webcast: | https://lifescievents.com/event/cassava/ |
A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.
Simufilam is an investigational oral, small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com
Media
media@cassavasciences.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
ir@cassavasciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.